ClinicalTrials.gg
SuspendedNCT04250311Updated Aug 18, 2023

Clinical Trial of Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient Adults

A Phase 3 interventional study of MMH-407 and Placebo in Influenza, sponsored by Materia Medica Holding. Suspended at 20 sites in Russian Federation. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2023-08-18.

Sponsored by Materia Medica Holding · Phase 3, Interventional, and Treatment

Why this study was suspended
Due to the end of the ARVI and influenza season, it was suspended until approximately October 01, 2023

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
314
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies in Influenza, Human with a site in Russian Federation — 2 open to participants now, 2 under way, 1 of them phase 3. Influenza, Human · Russian Federation.

Planned enrollment
25th of 59
314 · median 240
Started
2019
with 5 others
Phase 3
26 of 63
1 open now
Registered
36th of 63
by date
Lead sponsor
4 of 63
Materia Medica Holding

Among the 63 studies in Influenza, Human with a site in Russian Federation, this one is the 25th largest by planned enrollment of the 59 interventional ones that give a count, is one of 6 that started in 2019, is one of 26 in phase 3, and was the 36th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

2 of the 63 studies in Influenza, Human with a site in Russian Federation are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Influenza, Human with a site in Russian Federation, or all of them as a file.
02

Study summary

The main purpose of this study is:

  • to evaluate the efficacy and safety of MMH-407 in the treatment of influenza in outpatient adults.
Read the detailed description

Design: a multicenter, placebo-controlled, double-blind, randomized clinical trial in parallel groups.

The study will include both male and female patients aged 18-64 years with clinical signs of influenza within the first 24 hours of the onset of illness.

The influenza diagnosis must be supported by a positive rapid test (detection of influenza virus antigens in nasal epithelial cells). After the patients provide signed Participant Information Sheet and Informed Consent form, their medical history and body temperature will be recorded and physical examination and rapid diagnostic test performed. Patients who test positive will be assessed for 7 influenza-associated symptoms: cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, fatigue.

4-point Flu Symptom Severity scale will be used: 0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom.

Nasopharyngeal swabs will be obtained from these patients for subsequent real-time reverse transcription polymerase chain reaction (RT-PCR) influenza A/B testing and laboratory tests performed.

If a patient meets all inclusion criteria and does not meet any of the exclusion criteria at Visit 1 (Day 1), he/she will be randomized into one of the treatment groups: Group 1: ММН-407 for 5 days, or Group 2: Placebo on the ММН-407 regimen for 5 days.

The patients will use electronic patient diaries to daily record their morning and evening axillary temperature (taken using a Geratherm mercury-free thermometer) and severity of 7 influenza-associated symptoms (using the Flu Symptom Severity scale). In addition to this, the patients will record doses of antipyretic drugs taken (when applicable) and any worsening of their health status (when applicable, to assess treatment safety and collect adverse events data).

In total, patients will be observed for 14 days (screening and randomization - up to 24 hours, treatment - 5 days, subsequent observation - up to 2 days; and a follow-up 'telephone' visit - Day 14).

During the study, 3 visits from patient to the physician's office and a follow-up telephone visit will be accomplished: 1) patient visits - Days 1, 3 and 7 (Visits 1, 2, and 3) at the medical centre; 2) telephone visit from the physician (Visit 4) - Day 14.

During Visits 2 and 3, the physician will perform a physical examination, record the changes in patients' symptoms and the use of concomitant medications and check the completion of patient diaries. At Visit 2, nasopharyngeal swabs for RT-PCR will be collected. Visit 3 will involve an assessment of treatment compliance and laboratory tests. The telephone visit is intended to provide information on a patient's health status, presence/absence of secondary bacterial complications and the use of antibiotics.

During the study, subjects will be allowed to use symptomatic therapy and medications for their co-morbidities, except for the medicines listed in the "Prohibited Concomitant Medications" section.

03

Conditions studied

  • Influenza

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients of male and female gender aged 18 to 64 years.
  2. Uncomplicated, moderate influenza supported by all the symptoms:

    • axillary temperature ≥38.1°С on physician examination;
    • at least one moderate general symptom of influenza infection (headache, fever/chill, aches in the muscles/joints, weakness/drowsiness);
    • at least one moderate respiratory symptom of influenza infection (cough, sore throat, or nasal congestion).
  3. Positive influenza rapid test (detection of virus antigens in the nasal epithelium).
  4. First 24 hours of the onset of illness.
  5. Patients who agree to use a reliable method of during the study.
  6. Patients who have provided signed Participant Information Sheet and form to participate in a clinical trial.

Exclusion criteria

Exclusion Criteria:

  1. Severe influenza infection that requires hospitalization.
  2. Suspected pneumonia or bacterial infection (including otitis media, sinusitis, urinary tract infection, meningitis, sepsis, etc.) that requires the use of antibiotics, starting from the first day of illness.
  3. Suspected early manifestations of a condition that, on its first onset, produces symptoms similar to those of influenza (other infectious diseases and/or influenza-like syndrome associated with the first onset of a systemic connective tissue disorder or another condition).
  4. Patients who require the use of antivirals that are not permitted during the study.
  5. Current season influenza vaccination.
  6. Prior history or diagnosis of primary or secondary immunodeficiency
  7. Patients with any known or suspected malignant neoplasm.
  8. An exacerbated or decompensated chronic disease interfering with the subject's participation in the clinical trial.
  9. Malabsorption syndrome, including congenital or acquired lactase deficiency (or any other disaccharidase deficiency), and/or galactosemia.
  10. Current allergy to or intolerance of the active substances or any of the in the medications used in the treatment.
  11. Pregnancy, breast-feeding, childbirth within less than 3 months prior to the inclusion in the trial, or unwillingness to use methods during the study
  12. Prior history of non-adherence to medication; mental disorder; or alcohol or substance abuse, which, in the investigator's opinion, will compromise compliance with study procedures.
  13. Use of any of the "Prohibited Concomitant Medications" within 2 weeks prior to study entry.
  14. Patients who, as judged by the investigator, will fail or be unwilling to comply with the observation requirements or adhere to the dosing regimen during the study.
  15. Participation in other clinical studies within 3 months prior to the inclusion in this study.
  16. Patients who are related to any of the on-site research personnel directly involved in the conduct of the study or are an immediate relative of the investigator. 'Immediate relative' means husband, wife, parent, son, daughter, brother, or sister (regardless of whether they are natural or adopted).
  17. Patients who work for OOO "NPF "Materia Medica Holding" (i.e. company employees, temporary contract workers, designated officials responsible for carrying out the research or any immediate relatives of the aforementioned).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
314 participants (estimated)

Study arms

  • Experimental
    MMH-407

    Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day. Days 2 to 5: 1 tablet 3 times daily.

    Drug: MMH-407

  • Placebo comparator
    Placebo

    Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day. Days 2 to 5: 1 tablet 3 times daily.

    Drug: Placebo

Interventions

  • MMH-407: For oral use.

    Also known as: Raphamin

  • DrugPlacebo

    Placebo: For oral use.

06

What researchers measure

Primary outcomes

  1. Time to improvement of influenza symptoms.

    Based on patient diaries. In the morning and in the evening, the patients rate the severity of their symptoms on a 4-point scale (7 symptoms of influenza): headache, fever/chill, aches in the muscles/joints, weakness/drowsiness, cough, sore throat, and nasal congestion, where the absence of symptoms is 0, mild symptoms - 1, moderate symptoms - 2, and severe symptoms is 4. "Improvement of influenza symptoms" means no or mild symptoms.

    Time frame: On days 1-14 of observation.

Secondary outcomes

  1. Proportion of patients reporting improvement of influenza symptoms.

    Based on patient diaries.

    Time frame: On days 1-14 of observation period.

  2. Severity of illness.

    Total symptom score AUC (to be estimated from each of the seven symptom subscores).

    Time frame: On days 1- 6 of the observation period.

  3. Proportion of patients with negative virus shedding.

    Negative influenza RT-PCR on nasopharyngeal swabs.

    Time frame: On day 3 of the observation period.

  4. Dosing frequency of antipyretics according to indications.

    A decrease dosing frequency of antipyretics while taking MMN-407 is one of the criteria for effectiveness. Based on patient diaries.

    Time frame: On days 1-3 of the treatment period.

  5. Proportion of subjects reporting worsening of illness.

    Worsening of illness is bacterial complication of influenza that require the use of antibiotics or hospitalization.

    Time frame: On days 4 -14 of the observation period.

  6. Occurrence and nature of adverse events (AE).

    AE severity, causal relationship to the study drug and outcome.

    Time frame: On days 1-5 of the treatment period.

  7. Number of patients with treatment-related changes in vital signs: body temperature, pulse rate (heart rate), respiration rate (breathing rate), and blood pressure.

    Based on medical records. Vital signs will be measured in a medical setting.

    Time frame: On days 1- 5 of the treatment period.

  8. Proportion of subjects with clinically significant abnormal laboratory data.

    Вased on medical records.

    Time frame: On days 1- 5 of the treatment period.

07

Study locations

20 sites
  • City Hospital # 5
    Barnaul, 656045, Russian Federation
  • Belgorod State National Research University, Hospital Therapy Department
    Belgorod, 308015, Russian Federation
  • Road Clinical Hospital at Chelyabinsk station of JSC Russian Railways
    Chelyabinsk, 454000, Russian Federation
  • City Clinical Hospital # 9 of the Ministry of Health of the Udmurt Republic
    Izhevsk, 426063, Russian Federation
  • Kazan State Medical University, Internal Medicine Department
    Kazan, 420012, Russian Federation
  • Kuban State Medical University, Infectious Diseases and Phthisiopulmonology Department
    Krasnodar, 350063, Russian Federation
  • Central Clinical Hospital of the Russian Academy of Sciences
    Moscow, 117593, Russian Federation
  • City Clinical Hospital # 10 of the Kanavinsky District of Nizhny Novgorod
    Nizhny Novgorod, 603011, Russian Federation
  • Road Clinical Hospital at the station Nizhny Novgorod of JSC Russian Railways
    Nizhny Novgorod, 603140, Russian Federation
  • Vvedensky City Clinical Hospital
    Saint Petersburg, 191180, Russian Federation
  • City Polyclinic # 25 of the Nevsky District
    Saint Petersburg, 193312, Russian Federation
  • Medical Center "Reavita Med SPb"
    Saint Petersburg, 194354, Russian Federation
  • Llc "Medical Clinic"
    Saint Petersburg, 194356, Russian Federation
  • City Polyclinic # 43
    Saint Petersburg, 198207, Russian Federation
  • Samara City Hospital # 4
    Samara, 443056, Russian Federation
  • Scientific Medical Center for General Therapy and Pharmacology
    Stavropol, 355000, Russian Federation
  • Tver State Medical University, Department of Hospital Therapy
    Tver, 170100, Russian Federation
  • Bashkir State Medical University, Internal Medicine Department
    Ufa, 450008, Russian Federation
  • Volgograd State Medical University
    Volgograd, 400131, Russian Federation
  • Altai State Medical University, Department of Faculty Therapy with a course of immunology and allergology
    Barnaul, Москва 656038, Russian Federation
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2019 (actual). Primary completion is estimated for Dec 2024, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2020
First posted
Jan 31, 2020
StartActual
Dec 12, 2019
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2024
Last update
Aug 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04250311
Responsible party
Sponsor
First posted
Jan 31, 2020
Start date
Dec 12, 2019
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Aug 18, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MMH-407

Start the discussion